Revolutionizing the Treatment of Autoimmune Diseases
Addressing significant unmet needs in the field of autoimmunity through the development of novel patented therapies for treatment of disease.
AnTolRx’s vision is to build a platform that selectively targets pathogenic immune cells providing a unique tolerogenic signal to induce an anti-inflammatory phenotype and better treat diseases.
We are excited to attend the 38th annual J.P. Morgan Healthcare Conference in San Francisco, CA on January 13th through the 16th.
We will be attending the symposium "New Frontiers in Therapies for Celiac Disease". Join us at the University of Chicago (Chicago, IL) on November 23, 2019.